Merck & Co (MRK)

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of its mission to save and improve lives. It demonstrates its commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases - as we aspire to be the premier research-intensive biopharmaceutical company in the world.

Company profile

Kenneth Frazier
Fiscal year end
Former names
7728026 Canada Inc. • Abmaxis Inc. • Acceleron Holding Ltd. • Acceleron Pharma Canada Inc. • Acceleron Pharma Germany GmbH • Acceleron Pharma Inc. • Acceleron Pharma Netherlands BV • Acceleron Pharma Switzerland AG • Acceleron Securities Corp. • Afferent Pharmaceuticals, Inc. ...
IRS number

MRK stock data


4 Aug 22
12 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 9.75B 9.75B 9.75B 9.75B 9.75B 9.75B
Cash burn (monthly) (no burn) (no burn) (no burn) (no burn) 111.33M (no burn)
Cash used (since last report) n/a n/a n/a n/a 162.07M n/a
Cash remaining n/a n/a n/a n/a 9.59B n/a
Runway (months of cash) n/a n/a n/a n/a 86.1 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
3 Aug 22 David Michael Williams RSU Common Stock Grant Acquire A No No 0 17,119 0 17,119
3 Aug 22 Chirfi Guindo RSU Common Stock Grant Acquire A No No 0 110,705 0 110,705
30 Jun 22 Wendell Peter C Phantom Stock Common Stock Grant Acquire A No No 91.17 329.056 30K 115,036.434
71.1% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 2766 2731 +1.3%
Opened positions 177 371 -52.3%
Closed positions 142 135 +5.2%
Increased positions 1323 1183 +11.8%
Reduced positions 945 893 +5.8%
13F shares Current Prev Q Change
Total value 147.89B 139.91B +5.7%
Total shares 1.8B 1.83B -1.3%
Total puts 16.11M 24.5M -34.2%
Total calls 24.08M 34.99M -31.2%
Total put/call ratio 0.7 0.7 -4.5%
Largest owners Shares Value Change
Vanguard 216.1M $17.73B +2.3%
BLK Blackrock 204.12M $16.75B +3.0%
STT State Street 118.32M $9.79B -0.3%
Wellington Management 45.7M $3.75B -8.4%
Geode Capital Management 44.41M $3.63B -7.8%
BAC Bank Of America 36.43M $2.99B +2.9%
BK Bank Of New York Mellon 32.79M $2.69B +5.9%
Charles Schwab Investment Management 30.08M $2.47B +3.7%
NTRS Northern Trust 29.74M $2.44B -0.9%
Massachusetts Financial Services 28.84M $2.37B -0.5%
Largest transactions Shares Bought/sold Change
Norges Bank 0 -23.79M EXIT
BEN Franklin Resources 18.21M -15.85M -46.5%
Capital International Investors 1.87M -15.02M -88.9%
Marshall Wace 6.79M +6.75M +17260.2%
BLK Blackrock 204.12M +5.9M +3.0%
Renaissance Technologies 5.1M +4.92M +2671.4%
Vanguard 216.1M +4.89M +2.3%
BCS Barclays 4.25M -4.4M -50.9%
Wellington Management 45.7M -4.17M -8.4%
MS Morgan Stanley 25.49M -3.93M -13.4%

Financial report summary

  • Risks Related to the Company’s Business
  • The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected.
  • As the Company’s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.
  • Key products generate a significant amount of the Company’s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company’s results of operations and financial condition.
  • The Company’s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; in consequence, the Company may not be able to replace sales of successful products that lose patent protection.
  • The Company’s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.
  • The Company faces continued pricing pressure with respect to its products.
  • Unfavorable or uncertain economic conditions, together with cost-reduction measures being taken by certain governments, could negatively affect the Company’s operating results.
  • The Company faces intense competition from lower cost generic products.
  • The Company faces intense competition from competitors’ products.
  • In 2021 and 2020, COVID-19-related disruptions had an adverse impact on the Company’s business, operations and financial performance. The Company is unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic or similar public health threat will adversely impact its business, operations, financial performance, results of operations, and financial condition.
  • The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company’s results of operations and financial condition.
  • Failure to attract and retain highly qualified personnel could affect the Company’s ability to successfully develop and commercialize products.
  • The Company may experience difficulties and delays in manufacturing certain of its products, including vaccines.
  • The Company may not be able to realize the expected benefits of its investments in emerging markets.
  • The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.
  • Pharmaceutical products can develop unexpected safety or efficacy concerns.
  • Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company’s business.
  • Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition.
  • Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company’s future results of operations and financial condition.
  • Risks Relating to Government Regulation and Legal Proceedings
  • The health care industry in the U.S. has been, and will continue to be, subject to increasing regulation and political action.
  • The Company’s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.
  • Developments following regulatory approval may adversely affect sales of the Company’s products.
  • The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.
  • Adverse outcomes in current or future legal matters could negatively affect Merck’s business.
  • Product liability insurance for products may be limited, cost prohibitive or unavailable.
  • Risks Related to Technology
  • The Company is increasingly dependent on sophisticated software applications and computing infrastructure. In 2017, the Company experienced a network cyber-attack that led to a disruption of its worldwide operations, including manufacturing, research and sales operations. The Company could be a target of future cyber-attacks.

Content analysis

H.S. sophomore Avg
New words: ADC, antibody, antigen, arrangement, begun, blockade, breach, Bulgaria, ceiling, center, Chew, civil, Columbia, Consumer, contend, counting, CRT, cytochrome, deadline, diversion, docetaxel, dog, endocrine, enzyme, Estonia, experimental, forum, Fraud, fulfilled, gave, gBRCAm, HRSA, IB, IIIA, induction, intervene, LEAP, lost, lymph, median, MMWR, modest, nationwide, neurological, node, Orion, overcharging, plaintiff, point, prohibit, prohibited, Quebec, rebate, Romanian, routine, security, Sichuan, Slovenia, steroid, strike, trophoblast, uHCC, unanimously, undergone, unlawful, unnamed, warranty
Removed: adjourned, anticompetitive, API, argument, aware, bilateral, Brazil, claim, denying, fill, formulate, Francisco, fully, lack, Minnesota, NDA, PDUFA, recovery, removed, San, submitted, UHC, venue, violated